GlobeNewswire Inc | Oct 30, 2020 08:00AM EDT

October 30, 2020

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (Chi-Med) (Nasdaq/AIM: HCM) today announces that Mr. Christian Hogg, Chief Executive Officer of Chi-Med, will present or participate in the following virtual conferences:

-- The 15th Citi China Investor Conference on Thursday, November 5, 2020; and -- The China Summit Survey Results: Where is the "Bridge to Innovation" Headed? Panel as part of the BioCentury-BayHelix 7th China Healthcare Summit on Monday, November 9, 2020.

Members of the management team will attend the above conferences in one-on-one meetings, and will also attend the following virtual investor conferences at certain times:

-- The Bank of America 2020 China Conference held from November 2 to 13, 2020; -- The Goldman Sachs Asia Pacific Healthcare Forum held from November 16 to 18, 2020; -- The 11th Annual Jefferies Global Healthcare Conference held from November 17 to 19, 2020; -- The Morgan Stanley Asia Pacific Summit held from November 18 to 20, 2020; and -- The Piper Sandler 32nd Annual Healthcare Conference held from December 1 to 3, 2020.

Further information are available at www.chi-med.com in the Shareholder Information section under Events, Circulars & Forms.

About Chi-Med

Chi-Med (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of nine cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Meds filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

CONTACTS

Investor Enquiries Mark Lee, Senior Vice President +85221218200Annie Cheng, Vice President +1(973)5673786 Media Enquiries Americas ? Brad Miles, Solebury Trout +1(917)5707340(Mobile) bmiles@troutgroup.com +442037271030 / +447771913902Europe ? Ben Atwell / Alex Shaw, FTI (Mobile) /Consulting +447779545055(Mobile) Chi-Med@fticonsulting.com +85298505033 (Mobile),Asia ? Joseph Chi Lo / Zhou Yi, jlo@brunswickgroup.com /Brunswick +85297836894(Mobile), y zhou@brunswickgroup.com Nominated Advisor Freddy Crossley / Atholl Tweedie, +44(20)78862500PanmureGordon(UK)Limited